C Goldberger1, J D Guelfi1, D V Sheehan1. 1. Dr. Goldberger, MD, PhD, Clinical Research Physician, Lilly Research Laboratories, Indianapolis, IN. Dr. Guelfi, MD, Professor of Psychiatry, CMME, Ste Anne Hospital, Paris, France. Dr. Sheehan, MD, MBA, Distinguished University Health Professor, Professor of Psychiatry, Director, Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, Tampa, FL.
Abstract
BACKGROUND: The Hamilton Depression Rating Scale (HAMD17) is an outcome measure widely used in major depressive disorder (MDD) clinical trials. The objective of this analysis was to assess the validity of the anxiety/somatisation factor of the HAMD17 as a measure of anxiety in patients with MDD. METHODS: We pooled data from 1466 outpatients with MDD from four 8-week controlled studies of duloxetine. We performed a factor analysis of the HAMD17 to investigate the anxiety/somatisation factor. RESULTS: The HAMD17 factor analysis yielded 6 factors, but did not yield the pre-specified anxiety/somatisation factor. This latter factor showed weak correlation with the Hamilton Anxiety Scale total and subscale scores at baseline (0.46), but higher correlation coefficients over the trials up to 0.81. We identified another anxiety factor that included the hypochondriasis item in this sample. CONCLUSION: Findings from this large sample suggest that the factor structure of the HAMD17 is unstable in MDD and that the anxiety/somatisation subscale should not be routinely used for anxiety assessment in depressed patients.
BACKGROUND: The Hamilton Depression Rating Scale (HAMD17) is an outcome measure widely used in major depressive disorder (MDD) clinical trials. The objective of this analysis was to assess the validity of the anxiety/somatisation factor of the HAMD17 as a measure of anxiety in patients with MDD. METHODS: We pooled data from 1466 outpatients with MDD from four 8-week controlled studies of duloxetine. We performed a factor analysis of the HAMD17 to investigate the anxiety/somatisation factor. RESULTS: The HAMD17 factor analysis yielded 6 factors, but did not yield the pre-specified anxiety/somatisation factor. This latter factor showed weak correlation with the Hamilton Anxiety Scale total and subscale scores at baseline (0.46), but higher correlation coefficients over the trials up to 0.81. We identified another anxiety factor that included the hypochondriasis item in this sample. CONCLUSION: Findings from this large sample suggest that the factor structure of the HAMD17 is unstable in MDD and that the anxiety/somatisation subscale should not be routinely used for anxiety assessment in depressedpatients.
Entities:
Keywords:
Anxiety; Depression; Duloxetine; Factor structure; Hamilton
Authors: Michael J Detke; Curtis G Wiltse; Craig H Mallinckrodt; Robert K McNamara; Mark A Demitrack; Istvan Bitter Journal: Eur Neuropsychopharmacol Date: 2004-12 Impact factor: 4.600
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Maurizio Fava; A John Rush; Jonathan E Alpert; G K Balasubramani; Stephen R Wisniewski; Cheryl N Carmin; Melanie M Biggs; Sidney Zisook; Andrew Leuchter; Robert Howland; Diane Warden; Madhukar H Trivedi Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Kristin Köhler-Forsberg; Brice Ozenne; Søren V Larsen; Asbjørn S Poulsen; Elizabeth B Landman; Vibeke H Dam; Cheng-Teng Ip; Anders Jørgensen; Claus Svarer; Gitte M Knudsen; Vibe G Frokjaer; Martin B Jørgensen Journal: Transl Psychiatry Date: 2022-07-11 Impact factor: 7.989
Authors: Jennifer L Kruse; Richard Olmstead; Gerhard Hellemann; Elizabeth C Breen; Susannah J Tye; John O Brooks; Benjamin Wade; Eliza Congdon; Randall Espinoza; Katherine L Narr; Michael R Irwin Journal: J Psychiatr Res Date: 2021-06-09 Impact factor: 5.250